Article Information
History
- October 4, 2018.
Article Versions
- Version 1 (August 7, 2018 - 13:09).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Yotam E. Bar-Ephraim1,2,8,
- Kai Kretzschmar1,2,8,
- Priyanca Asra1,2,
- Evelien de Jongh1,2,
- Kim E. Boonekamp1,2,
- Jarno Drost3,
- Joost van Gorp4,
- Apollo Pronk5,
- Niels Smakman5,
- Inez J. Gan6,
- Zsolt Sebestyén6,
- Jürgen Kuball6,
- Robert G.J. Vries7 and
- Hans Clevers1,2,3,*
- 1Oncode Institute, Hubrecht Institute, Royal Netherlands Academy for Arts and Sciences (KNAW) and University Medical Centre (UMC) Utrecht, the Netherlands
- 2UMC Utrecht, Cancer Genomics Netherlands, Utrecht, the Netherlands
- 3Princess Máxima Centre for Paediatric Oncology, Utrecht, the Netherlands
- 4Department of Pathology, Diakonessenhuis hospital, Utrecht, the Netherlands
- 5Department of Surgery, Diakonessenhuis hospital, Utrecht, the Netherlands
- 6Laboratory of Translational Immunology, Department of Immunology, UMC, Utrecht, the Netherlands
- 7Foundation Hubrecht Organoid Technology (HUB), Utrecht, the Netherlands
- ↵*Corresponding author, e-mail: h.clevers{at}hubrecht.eu
↵8 These authors contributed equally: Yotam E. Bar-Ephraim, Kai Kretzschmar